RonCohenMD

Internal Medicine • Ardsley, NY

Physician

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cohen's full profile

Already have an account?

Office
Acorda Therapeutics
420 Saw Mill River Road
Ardsley, NY 10502
Phone+1 914-326-5101
Is this information wrong?

Education & Training

University of Virginia Medical CenterResidency, Internal Medicine, 1981 - 1984
Columbia University Vagelos College of Physicians and SurgeonsClass of 1981

Certifications & Licensure

CA State Medical License 1990 - Present
NY State Medical License 1984 - 2024
NV State Medical License 1993 - 1999
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

1 citations
Chinese scientists and US leadership in the life sciences.
Steven H Holtzman, Ron Cohen, Jeremy M Levin, John M. Maraganore> ;Nature Biotechnology. 2019 Nov 1
Proposals to Lower Medication Costs.
Ron Cohen, Jeremy M Levin, John M. Maraganore> ;JAMA. 2019 Sep 10
Biotech leaders call for free press.
Cohen, R.,Holtzman, S.,Levin, J. M.,Maraganore, J. M.> ;Nat. Biotechnol.. 2018 Oct 12
2 citations
US immigration order strikes against biotech
Jeremy M Levin, Steven H Holtzman, John M. Maraganore, Paul Hastings, Ron Cohen, Bassil Dahiyat, Julian Adams, Chris Adams, Brett Ahrens, Jeff Albers, Mara G Aspinall,...> ;Nature Biotechnology. 2017 Mar 7
1 citations
Important Distinctions Concerning Pharmaceutical Company-Sponsored Meals and Prescribing Patterns.
Ron Cohen> ;JAMA Internal Medicine. 2016 Dec 1
41 citations
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
Andrew D. Goodman, Francois Bethoux, Theodore R Brown, Randall T Schapiro, Ronald A. Cohen, Lawrence Marinucci, Herbert R. Henney, Andrew R. Blight, Extension Study In...> ;Multiple Sclerosis. 2015 Jan 12
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight, A. R.,Henney, H. R.,Cohen, R.> ;Ann. N. Y. Acad. Sci.. 2014 Aug 27
30 citations
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
Diana D. Cardenas, John F. Ditunno, Virginia Graziani, Amie McLain, Daniel P. Lammertse, Patrick J. Potter, M S Alexander, Ron Cohen, Andrew R. Blight> ;Spinal Cord. 2014 Jan 1
Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study.
Zhu, T.,Zhong, J.,Hu, R.,Tivarus, M.,Ekholm, S.,Harezlak, J.,Ombao, H.,Navia, B.,Cohen, R.,Schifitto, G.> ;J Neurovirol. 2013 Feb
247 citations
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Andrew D. Goodman, Theodore R Brown, Keith R. Edwards, Lauren B. Krupp, Randall T Schapiro, Ron Cohen, Lawrence Marinucci, Andrew R. Blight> ;Annals of Neurology. 2010 Oct 1
378 citations
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D. Goodman, Theodore R Brown, Lauren B. Krupp, Randall T Schapiro, Steven R. Schwid, Ron Cohen, Lawrence Marinucci, Andrew R. Blight> ;Lancet. 2009 Feb 28
130 citations
Dose comparison trial of sustained-release fampridine in multiple sclerosis
Andrew D. Goodman, Theodore R Brown, Jeffrey A. Cohen, Lauren B. Krupp, Randall T Schapiro, Steven R. Schwid, Ron Cohen, Lawrence Marinucci, Andrew R. Blight> ;Neurology. 2008 Oct 7
53 citations
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Diana D. Cardenas, John F. Ditunno, Virginia Graziani, Amie B. Jackson, Daniel P. Lammertse, Patrick J. Potter, M Sipski, Ron Cohen, Andrew R. Blight> ;Spinal Cord. 2007 Feb 1
117 citations
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Andrew D. Goodman, Jeffrey A. Cohen, Anne H. Cross, Timothy Vollmer, Marco A. Rizzo, Ron Cohen, Lawrence Marinucci, Andrew R. Blight> ;Multiple Sclerosis. 2007 Jan 29
29 citations
Pharmacokinetics and Safety of Multiple Oral Doses of Sustained-Release 4-Aminopyridine (Fampridine-SR) in Subjects With Chronic, Incomplete Spinal Cord Injury
Keith C. Hayes, Patrick J. Potter, Jane T Hsieh, Mitchell A. Katz, Andrew R. Blight, Ron Cohen> ;Archives of Physical Medicine and Rehabilitation. 2004 Jan 1
Should Physicians Treat Patients Who Seek Second Opinions
Ron Cohen> ;JAMA. 1991 Nov 13
Transfer of delayed hypersensitivity by thymic extract.
Elias EG, Cohen RM> ;Ann. N. Y. Acad. Sci.. 1975-02-28
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Goodman, A. D.,Brown, T. R.,Schapiro, R. T.,Klingler, M.,Cohen, R.,Blight, A. R.> ;Int J MS Care. 2014 Oct 23
Join now to see all

Press Mentions

Acorda Therapeutics Reports Second Quarter 2021 Financial ResultsAugust 5th, 2021
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in SpainJuly 22nd, 2021
Covid Vaccines Will Deliver Long-Term Health Boost for DrugmakersJune 25th, 2021
Join now to see all

RonCohenMD

Dr. Cohen is on Doximity

Education & Training

Certifications & Licensure

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.